AmplifyBio and Xcell Biosciences: An Uncommonly Great Partnership for Cancer Therapy
Xcellbio and AmplifyBio have partnered to enhance the development and manufacturing of engineered T-cell receptor (TCR) therapies for solid...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Xcellbio and AmplifyBio have partnered to enhance the development and manufacturing of engineered T-cell receptor (TCR) therapies for solid...
Terran Biosciences has developed TerXT, a combination of novel prodrugs of xanomeline and trospium, for treating schizophrenia. The prodrug...
The DIA Europe 2024 conference brought together leading experts to discuss groundbreaking innovations and regulatory strategies in clinical trials....
Parallel Bio, a biotechnology company, has developed “Clinical Trial in a Dish,” a revolutionary platform that employs human models...
Karius, Inc., a pioneer in genomic diagnostics for infectious diseases, has received a Breakthrough Device designation from the FDA...
CinDome Pharma, a subsidiary of CinRx Pharma, has secured a $40 million extension to its Series B financing, raising...
Accenture Ventures, the venture capital arm of Accenture, has invested in Turbine, a predictive simulation company developing a platform...
A Phase IIa trial, known as COURSE, has assessed the effectiveness of TEZSPIRE (tezepelumab) in reducing COPD exacerbations in...
New data revealed that after four years of continuous treatment, over 70% of patients with psoriasis achieved a 75%...
Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative disorders, has shared its financial results and updated it for...